The text starts here.

News Release

FOR IMMEDIATE RELEASE
February 26, 1997

Eisai Receives Marketing Clearance In UK For ARICEPT(TM) (donepezil hydrochloride), A New Symptomatic Treatment For Alzheimer's Disease

Tokyo (February 26, 1997) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that Eisai Europe Ltd., an Eisai UK subsidiary, received a marketing authorisation from the UK Medicines Control Agency (MCA) for ARICEPT(TM) (donepezil hydrochloride) or E2020, a new drug for the symptomatic treatment of mild to moderate dementia in Alzheimer's disease on February 19, 1997.


Eisai Europe Ltd. submitted the application to the UK MCA as the first evaluator (reference member state) in European Union (EU) countries in September 1996. Eisai will seek further marketing authorisations in other EU countries through the mutual recognition procedure using the United Kingdom as the reference member state.


ARICEPT(TM) will be co-promoted in the UK by Eisai Ltd. and Pfizer Ltd., a subsidiary of Pfizer Inc.


ARICEPT(TM) is a novel acetylcholinesterase inhibitor synthesized by Eisai in Japan, and is being developed by Eisai in Japan, Europe and in the US. ARICEPT(TM) was approved for marketing as a new drug for the symptomatic treatment of mild to moderate dementia of the Alzheimer's type by the US Food and Drug Administration (FDA) in November 1996. The compound is in the Phase III clinical trial stage in Japan.


Pfizer Inc is a research-based health care company with global operations. In 1996, the company reported sales of more than $11 billion and, in 1997, anticipates investing approximately $2 billion on research and development.


Eisai Co., Ltd. is a research based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of $2.6 billion in 1995 with approximately 14 percent of sales spent for research and development.


ARICEPT(TM) is a trademark of Eisai Co., Ltd.